An automated CT readout of imaging changes (2 related to tumor size and 2 to phenotype) from baseline to 6 months post-initiation of pembro for advanced melanoma better predicted overall survival than standard RECIST criteria when applied to enrollees on a prospective clinical trial. | Dercle, JAMA Oncol 2022


Popular Posts